The Mount Sinai Division of Gynecologic Oncology
Physicians in the Division of Gynecologic Oncology are internationally recognized for their advanced training, diagnosis and treatment capabilities for women with gynecologic cancer including ovarian cancer, cervical cancer, uterine (endometrial) cancer, vaginal and vulvar cancer. Our physicians are skilled surgeons and practiced in the delivery and principles of chemotherapy and radiation and all have spent considerable time in the laboratory. This results in a seamless and integrative approach to cancer management that is unique to Mount Sinai.
Our therapeutic and surgical procedures are offered in collaboration with leading Mount Sinai experts in early detection, diagnostic and interventional radiology, genetics, radiation therapy, palliative care, behavioral medicine, nutrition, physical therapy and one-on-one support from survivors of gynecologic cancer. We practice in the world renowned Tisch Cancer Institute to evaluate and manage surgical patients and we administer chemotherapy in the Ruttenberg Cancer Treatment Center, a unified, state-of-the-art setting designed to ensure patient privacy and comfort. Our nurses are specifically trained in cancer treatment services and our on-site oncology pharmacists use the most up-to-date treatment protocols.
The Ovarian Cancer Translational Research Group at Mount Sinai
Under the leadership of Peter Dottino, MD, Director of the Division of Gynecologic Oncology, and John Martignetti, MD, PhD, Associate Professor, Departments of Genetics and Genomics and Oncological Sciences, we are intent on finding markers for early detection and prevention of ovarian cancer by identifying molecules that tumors secrete which could be detected by a blood test to possibly signal the earliest stages
of tumor formation or response to different treatments.
The Mount Sinai Ovarian Cancer Risk Assessment Program
The program is a collaboration between a team of board certified gynecologic oncologists and genetic researchers at The Tisch Cancer Institute and across the country, led by David Fishman, MD, Professor, Department of Obstetrics, Gynecology and Reproductive Science, dedicated to using molecular biology and genetics to identify women at risk before they develop ovarian cancer and to examine the role of immune-based interventions.
More than 200 women have enrolled in the ongoing study which also includes collection of blood samples, ascites fluid, and cell lines established from their tumors in an international collaboration with Memorial Sloan Kettering Cancer Center, New York; MD Anderson Cancer Center, Houston, Texas; British Columbia Cancer Agency, Vancouver, Canada; and the Mario Negri Research Institute in Milan, Italy.
The data we have been collecting is incredibly rich and is providing us with an unprecedented view into the identity of these tumor cells. One example is a research finding that Mount Sinai investigators made when working on the KLF6 gene, a tumor suppressor gene that stops cancer from developing. A variation in this gene drives cells to grow and metastasize. Our research team showed that treatment with certain chemical compounds attacked this genetic variation, and the survival rate tripled. This work was recently published in the prestigious journal Cancer Research and as a chapter in the book The Biology of the Kruppel-like Factors (Springer).
Together, Mount Sinai and VOICE are leading the effort toward diagnosing ovarian cancer in its earliest stages; providing critical clinical and support services to women at risk and their families; funding research that will lead to breakthroughs in early detection; and educating legislators and the public of the importance of early detection of ovarian cancer and prevention. Our goal is to improve women’s health care and save women’s lives.
The sculpture, “Ribbons of Hope” was used as the theme for our 2007 Dinner Dance. It was designed by Florida sculpture Will Grant. It’s ever-changing colors, depending on the refraction of light, represent the excitement of life and as it reaches upward, our hope for the future.